Tag : clinical operations

As the Cost of Clinical Trials Climbs, Here Are 3 Ways to Save

By all accounts, the cost of clinical trials continues to rise. We hear reasons that include increasing protocol complexity, patient recruitment struggles, or regulatory challenges. And we shrug our shoulders. Most of us accept these rising costs and obstacles as a given. But - why? If you could predict the future problems

• Posted on 29 Jun 2021
• By ArcheMedX Team
• In Clinical Research Blog

Continue Reading

A Decentralized Clinical Trial Requires Training at Scale. Here’s What That Means.

The decentralized clinical trial is one of the most talked-about emerging trends in the life sciences industry. These sorts of clinical trials present immense benefits, as we wrote about in a recent blog. If executed well, the decentralized clinical trial design could both reduce resource consumption and accelerate treatments arrival to

• Posted on 24 May 2021
• By ArcheMedX Team
• In Clinical Research Blog

Continue Reading

5 Challenges in Working with CROs – and How to Overcome Them

You have a clinical trial starting soon. Are you working with a contract research organization, or at least planning to do so? Probably. In 2020, the ACRP estimated that 70% of clinical trials would involve sponsors working with CROs. And, as a result, 100% of those sponsors will encounter some

• Posted on 21 May 2021
• By ArcheMedX Team
• In Clinical Research Blog

Continue Reading

How Can We Manage the Increasing Complexity of Clinical Trial Protocols?: Interview with Ken Getz of Tufts Center for the Study of Drug Development

Ken Getz joins Kelly Ritch, EVP of Product and Clinical Research Solutions at ArcheMedX, to discuss the growing complexity in clinical trial protocols. The Director of the Tufts Center for the Study of Drug Development and a Research Professor at the Tufts University School of Medicine, Ken shares his insights

• Posted on 21 May 2021
• By ArcheMedX Team
• In Clinical Research Blog, Interviews

Continue Reading

An Honest Look at How Demanding Oncology Trials Have Become: Interview with Rebecca Setta of Oncosec

Rebecca Setta joins Kelly Ritch, EVP of Product and Clinical Research Solutions at ArcheMedX, to discuss effective management of sites and teams through arduous clinical trials. Rebecca shares how she’s kept her team motivated and productive in spite of the added burdens imposed by the pandemic, and why she’s excited

• Posted on 20 Apr 2021
• By ArcheMedX Team
• In Clinical Research Blog, Interviews

Continue Reading

Got a Clinical Trial Startup Post-COVID? Plan to Tackle 3 Big Challenges

There are still a lot of challenges facing pharmaceuticals, med tech, and biotech companies that seek to begin a clinical trial post-COVID. But the obstacles aren’t stopping them. At time of writing, over 500 companies have a Phase II or Phase III clinical trial startup planned in the next 12

• Posted on 30 Mar 2021
• By ArcheMedX Team
• In Clinical Research Blog

Continue Reading

Decentralized, virtual, or hybrid clinical trial – what’s the difference?

Increased diversity. Faster enrollment. Reduction in costs. These are just a few of the myriad benefits of the virtual clinical trial touted by CROs and solution providers. But are you ready for a truly virtual clinical trial? If not, is a hybrid clinical trial realistic? And what is a decentralized

• Posted on 24 Mar 2021
• By ArcheMedX Team
• In Clinical Research Blog

Continue Reading

What Do You Do When You Don’t Have Enough Clinical Trial Locations: Interview with Krystyna Kowalczyk of Oncobay

Krystyna Kowalczyk joins Kelly Ritch, EVP of Product and Clinical Research Solutions at ArcheMedX, to discuss innovation and leadership in oncology clinical trials. The founder and CEO of OncoBay Clinical, Krystyna shares her efforts to break the mold when it comes to cancer research, and explores OncoBay's "just in time"

• Posted on 18 Mar 2021
• By ArcheMedX Team
• In Clinical Research Blog, Interviews

Continue Reading

When Seeking Diversity during Site Selection, Look Beyond Historical Data to Discover Untapped Patient Populations

We recently spoke with Liz Beatty, Chief Strategy Officer at Inato about how the company is disrupting the industry's approach to site selection. The company is headquartered in Paris, France, with US operations based in New York City, NY. Here are some of the most interesting excerpts from our discussion: ArcheMedX: You

• Posted on 24 Feb 2021
• By ArcheMedX Team
• In Clinical Research Blog, Interviews

Continue Reading

Helping Sites and Teams Make the Shift to Decentralized Trials: Interview with Paul Evans of Velocity Clinical Research

Paul Evans of Velocity Clinical Research talks with Kelly Ritch, EVP of Product and Clinical Research Solutions, to discuss best practices for sites making the shift toward decentralized trials. Paul shares how his own organization was able to pivot so quickly when the pandemic hit, why it’s too early to

• Posted on 17 Feb 2021
• By ArcheMedX Team
• In Clinical Research Blog, Interviews

Continue Reading